ImmunogenX, Inc.

5:15 PM - 5:30 PM (PDT), Tuesday, June 14, 2022 ・ Company Presentation Theater 4
ImmunogenX is a late clinical-stage therapeutic and diagnostic company focused on celiac disease (CeD). Both Rx and Dx treatments represent unmet needs for a critical disease and as developers of leading technologies we are positioned to be a Category King in the CeD market space.

There is a huge need for treatment options for CeD and the FDA is supportive of our plan to bringing these solutions to market.

We are completing our Phase 2 program, much of it funded by the NIH. We are in preparation for our Phase 3 trial to begin mid 2023.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Latiglutenase (IMGX003)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):